21 May

5 Things to Know Before Mark Zuckerberg’s European Parliament Testimony

Facebook CEO Mark Zuckerberg is due to testify before members of European Parliament (MEPs) tomorrow, in an appearance that was confirmed by President Antonio Tajani on Twitter last week.

Zuckerberg is due to appear before the Committee for Civil Liberties, Justice and Home Affairs (LIBE), where he’ll likely be asked questions about protecting the personal data of EU consumers, as well as Facebook’s role in election processes and integrity.

The session — which is scheduled to begin at roughly 6:15 PM local time in Brussels (12:15 PM EST) — was speculated and predicted by many in the weeks leading up to Tajani’s confirmation.

In addition to some outlets reporting that such a meeting was in the works, several events took place soon before and after the announcement that indicated another appearance from Zuckerberg before legal officials, ranging from official statements on Facebook’s new initiatives, to changes within its organizational chart.

Before Zuckerberg makes his next official appearance, here are some key things to know.

5 Things to Know Before Mark Zuckerberg’s European Parliament Testimony

1. The testimony was originally scheduled as a closed-door session.

Shortly after Tajani’s announcement, Bloomberg reported that Zuckerberg’s initial appearance before EU lawmakers would take place behind closed doors, and that European Parliament would schedule a separate, public hearing with representatives from Facebook that may not necessarily include Zuckerberg himself.

While a secondary hearing has yet to be scheduled, as of publishing this piece, Tajani announced this morning that Zuckerberg agreed to permit the session to be live-streamed — likely due to pressure from several parties, including MEPs.

In our own survey of 313 consumers in the UK — which was conducted prior to the announcement that the session would be live-streamed — 61% of respondents said that they believed the testimony should be public.

ed918eae-32c2-422a-b9b6-30ef20586470

Verhofstadt has since reversed his statement on the matter, after the decision to cast the session. However, the degree to which the event will be “public” is arguable, as it’s not clear if members of the press or other concerned public parties will be permitted to attend.

2. Not long before the testimony was originally announced, Facebook’s executive org chart had a major shakeup.

On May 8 — just over a week before Tajani’s confirmation that Zuckerberg would be testifying before MEPs — Recode reported a major shuffle to its executive organizational chart, with changes made among the leadership at WhatsApp, Messenger, Instagram, and the core Facebook app.

Here’s a visual peek at the overall changes:

In addition to the general re-org of leadership within existing Facebook teams and umbrella brands, a new team has been created to focus solely on privacy products, such as the Clear History feature announced at F8. 

When word of the executive shuffle first arrived, we anticipated that an official appearance from Zuckerberg could be imminent — especially with the creation of an entire division dedicated to one of the issues (privacy) for which Facebook has received the most scrutiny, and continues to answer the most questions.

But privacy isn’t the only topic for which Facebook has faced particularly heightened scrutiny — which brings up another important item to keep in mind going into tomorrow’s session.

3. The day after the testimony was announced, Facebook announced a partnership with the Atlantic Council for its election integrity efforts.

Facebook has also continued to receive criticism and questions about the weaponization of its platform by foreign actors to influence the 2016 U.S. presidential elections. Since then, consumers and authorities alike have been especially vigilant of the spread of misinformation and hate speech on the site, especially where divisive issues that often cause contention during election seasons are concerned.

That prompted Facebook to release its first-ever Community Standards Enforcement Report, which includes a preliminary inventory of rule-violating content and the action Facebook took on it between October 2017 to March 2018.

But it also led Facebook — whether strictly for appearances or out of genuine concern over the weaponization of its platform — to partner with outside experts to boost its election integrity efforts, which Zuckerberg is likely to be questioned on by MEPs.

To help combat “fake accounts – the source of many bad ads and a lot of misinformation,” Facebook has partnered with nonprofit Atlantic Council, whose mission includes “stimulating dialogue and discussion about critical international issues in the Administration, the Congress, corporate and nonprofit sectors, and the media among leaders in the U.S., Europe, Asia, and the Americas.” 

The Atlantic Council’s Digital Forensic Research Lab — the primary team partnering with Facebook — released a statement about the collaboration, in which it elaborated on that mission. Specifically, it pointed to the importance of closing the “information gap between governments, tech companies, and media in order to solve for challenges like disinformation.”

It was an interesting statement to make the day after it was first revealed that Zuckerberg’s session with MEPs would be a closed-door one, limiting the very transparency between governments and tech companies to which the statement alluded.

It also came after a recent and repeated refusal from Facebook of requests from UK Parliament for Zuckerberg to appear — which is another key item to note before tomorrow’s session.

4. UK Parliament has requested an appearance from Zuckerberg repeatedly — and Facebook has continued to decline.

On May 1 — just over two weeks prior to Tajani’s announcement — House of Commons Culture Committee chairman Damian Collins issued an open letter to Facebook UK Head of Public Policy Rebecca Stimson, stating that “the committee will resolve to issue a formal summons for [Zuckerberg] to appear when he is next in the UK.” 

In response to that letter, Stimson wrote a response on May 14th indicating that “Mr. Zuckerberg has no plans to meet with the committee or travel to the UK at the present time.”

Zuckerberg’s resolve to not appear before UK Parliament raises several questions. While other Facebook executives have undergone questioning from the committee, like CTO Mike Schroepfer, Zuckerberg himself has steadfastly refused to appear, despite committing to back-to-back U.S. congressional hearings, as well as tomorrow’s testimony before MEPs.

So, why the resistance to testifying before UK MPs?

One possible reason is that Zuckerberg’s appearances before U.S. lawmakers were voluntary — as will be his testimony before MEPs — whereas UK Parliament has reached the point of issuing a formal summons.

“It’s not entirely clear why Zuckerberg is resisting appearing before UK members of parliament,” says Henry Franco, HubSpot’s social media editor. “We know that the tone from the UK has been a fairly vindictive one, and we also know Zuckerberg (and Facebook) doesn’t want to open the door to negotiation and questioning from every governing body. They want a free and independent Facebook, which means answering the bare minimum number of questions necessary to keep it that way.”

5. The testimony is taking place three days before the General Data Privacy Regulation (GDPR) comes into force in the EU.

This Friday — three days after Zuckerberg’s scheduled testimony before MEPs — the GDPR comes into force in the EU, marking a major shift in European data privacy laws and consumer rights.

Whether the timing was deliberate is somewhat speculative, but it appears to be slightly more than coincidental — at least on the part of European Parliament. Facebook has received criticism for its approach to the GDPR, and Zuckerberg has frequently evaded questions about how he would apply similar protections to non-EU consumers, or backpedaled on previous answers to them.

Many wonder how these imminent regulations — which are much stricter than those, if any, in the U.S. — will influence MEPs’ lines of questioning tomorrow, and if those questions will reflect the tougher nature of European laws than those in the U.S.

The general consensus seems to be that, yes — they will. When we asked 302 consumers in the UK if they believe MEPs will be harder on Zuckerberg during tomorrow’s hearing than U.S. lawmakers were in April, 48% responded with “yes.”

UK_Do you think members of European Parliament will be tougher on Mark Zuckerberg during his testimony tomorrow than U.S. lawmakers were_302

In a survey of 303 U.S. consumers, meanwhile, 53% of respondents had the same answer.

US_Do you think members of European Parliament will be tougher on Mark Zuckerberg during his testimony tomorrow than U.S. lawmakers were_303

“My sense is that the big difference between the EU and the U.S., is that consumers in the U.S. kind of don’t care,” says HubSpot VP of Marketing Jon Dick. “We just assume we’re being taken advantage of and are okay with it.”

The heightened level of concern among European consumers, meanwhile, could be reflected in a tougher line of questioning from MEPs tomorrow.

“Consumers in the EU care. They want proper notice and controls, and they want companies to be held to account if they violate their data privacy,” Dick continues. “So my expectation is that EU Parliment will be far tougher on [him] than the U.S. Congress was.”

We’ll be following tomorrow’s testimony. According to a tweet from Carlo Corazza, a spokesperson for Tajani, the event will be live-streamed on European Parliament’s website

21 May

ORIC Pharmaceuticals Appoints Jacob Chacko CEO

Jacob Chacko has joined ORIC Pharmaceuticals to become the cancer drug developer’s CEO. Rich Heynman, who had been interim CEO, will now become chairman of the San Francisco company’s board of directors. Chacko was most recently chief financial officer of Ignyta, which was acquired by Roche earlier this year. ORIC, which stands for “overcoming resistance in cancer,” develops therapies for cancers that have become resistant to previous treatments. The company’s lead drug, ORIC-101, is in early-stage clinical testing.

UNDERWRITERS AND PARTNERS

          

          

            

20 May

Game of Thrones Composer Plays the Theme on a Nintendo Labo

Game of Thrones Composer Plays the Theme on a Nintendo Labo
Ramin Djawadi composed the awesome Game of Thrones theme but can he play it on a Nintendo Labo?
[Read More …]

18 May

Merck’s Roger Dansey Joins Seattle Genetics as Chief Medical Officer

Roger Dansey has been appointed chief medical officer of Seattle Genetics (NASDAQ: SGEN). Dansey comes to Bothell, WA-based SeaGen from Merck (NYSE: MRK), where he was a senior vice president in oncology. Dansey succeeds Jonathan Drachman, who will continue working with SeaGen as a strategic advisor. SeaGen develops and sells cancer therapies based on its antibody-drug conjugate technology.

UNDERWRITERS AND PARTNERS

          

          

            

18 May

Call for proposals for ERC Advanced Grant

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: ERC-2018-ADGPillar: Excellent SciencePlanned Opening Date: Deadline: Thu, 30 Aug 2018 17:00:00 (Brussels local time)Modification Date: Fri, 18 May 2018Latest information: The ERC-2018-ADG Call will open soon after 23 May 2018.

18 May

2017 Rosalind Franklin Award Recipient: CRISPR has the potential to address important challenges

As we’ve covered here before, gene editing holds tremendous promise in advancing modern agriculture. And it’s not hard to see why. With gene editing tools like CRISPR, researchers have the capability to engineer plants to be, amongst other things, better for the environment, more nutritious and disease-resistant.

BIO’s 2017 Rosalind Franklin Award for Leadership in Biotechnology recipient Vonnie Estes is an agtech innovation consultant who is tuned into the current conversations happening at farms and agricultural businesses across America. And a lot of those conversations revolve around the new gene editing technology.

In a blog for Ag Funder News, Estes entertains the question: Should You Be Using CRISPR for Your Ag Business? In addressing this question, Estes starts by outlining the “number of challenges” that must be addressed before CRISPR becomes widely adopted, including the regulatory landscape:

One of the biggest restrictions to the global commercial use of gene editing is uncertainty around regulation. The USDA just ruled it would not regulate plants that could otherwise have been developed through traditional breeding techniques, as long as they are not developed using plant pests. This is a good start, however, there are a limited number of improvements that can be made within these criteria. If Agrobacterium is used as a delivery method or a greater number of genes are edited – which will be needed for complex traits – it will be considered GMO and more highly regulated. Most crop genetics and food production companies operate globally: shipping seeds, plant materials, or final foods worldwide. The EU has not yet ruled if gene edited crops fall under the genetically modified organism rule, although there is some indication that may change. Until this is clear, many crop genetics companies will not risk the potential trade barriers of using gene editing technology.

Vonnie Estes, Agtech Innovation Consultant

Estes then goes on to note that because of the contentious debate around GMOs and the public’s confusion around the difference in the science behind the two technologies, gene editing will be susceptible to similar pushback. However, Estes believes the younger generation of consumers will be receptive, especially if the benefits are clearly defined and explained:

Consumers are more likely to accept the technology if they get a direct benefit, such as better taste or higher nutritional value. Food producers are right to be cautious, but I’m hoping the younger, tech-savvy, more demanding food consumers will be accepting of gene editing technology.

Nevertheless, the potential for the technology to solve some of the world’s food challenges is encouraging and the science community is enthusiastic:

As the world’s population rapidly approaches eight billion, modern food production methods will need a radical transformation. Gene editing can certainly help meet that challenge of production, along with making food more flavorful and nutritious. The path to widespread usage is currently complicated – from the science to consumer acceptance. But with the tremendous enthusiasm of the research community, gene editing technologies will improve rapidly along with the all of the techniques and technologies needed to support crop use.

Read Vonnie Estes full piece at AgFunderNews.com.

18 May

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines

An Amgen migraine drug developed to head off pain before it starts has won FDA approval, the first for a new class of preventive drug candidates for the condition.

The Amgen (NASDAQ: AMGN) drug, erenumab (Aimovig), is a subcutaneous injection given once a month. The drug blocks the receptor for calcitonin gene-related peptide (CGRP), a protein released by neurons that is thought to play a role in the start of migraine pain. In contrast to triptans, an older group of medications that patients take at the onset of pain, these CGRP drugs are meant to stop the activity that leads… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

17 May

OncoNano, Maker of Tumor Imaging Technology, Raises $11.7 Million

Dallas-OncoNano Medicine, which is developing an imaging agent to help surgeons better remove tumors, has raised $11.7 million in Series A funding.

OncoNano’s lead product, ONM-100, is an injectable imaging agent that targets the acidic pH within tumors to better distinguish cancer cells from healthy ones during surgery.

OncoNano said the new funding was arranged by Salem Partners, which also participated as a principal investor. The round included institutional and individual investors that the company did not name. The new investment follows a $6 million grant the company received from the Cancer Prevention and Research Institute of Texas (CPRIT).

Ravi… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

17 May

Better Health and care, economic growth and sustainable health systems

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-SC1-BHC-2018-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Tue, 16 Apr 2019 17:00:00 (Brussels local time)Modification Date: Thu, 17 May 2018Latest information: An overview of the evaluation results of the first stage (flash call info) for the topic SC1-BHC-15-2018 that closed on 06 February 2018 is now available under the “Topic conditions and documents” section on the topic page.

17 May

2018 World Congress: Start Planning with BIO’s Partnering Webinar

It’s hard to believe but the 2018 World Congress on Industrial Biotechnology in Philadelphia is only two months away! With the tri-state region of Delaware, New Jersey and Pennsylvania ranking as one of the top markets for biotechnology and home to many startups, this year’s World Congress is perfect for those looking to establish lasting partnerships in the industrial biotechnology industry.

The BIO One-on-One Partnering™ system takes the stress out of coordinating and scheduling meetings at the World Congress, so you can focus on your partnering strategy. Through BIO’s One-on-One Partnering, attendees can request meetings, message potential partners pre- and post-World Congress and create company profiles to showcase your company’s mission or latest breakthrough.

In case you missed it, BIO has put together a One-on-One Partnering Webinar to get you up to speed on how the system works. In the webinar, BIO’s Director of Partnering Products & Services Willie Reaves, along with BIO’s Director of Industrial and Environmental Policy Stephanie Batchelor, present a comprehensive overview of everything that can be accomplished in the platform.

From accessing attendee lists to reviewing programming and plenary details to strategies for getting the most out of your meetings, the Partnering Webinar covers everything you need to know to master BIO’s One-on-One Partnering system. Here’s a sneak preview of what is covered in the webinar:

  • What’s new at the 2018 BIO World Congress on Industrial Biotechnology
  • Comprehensive overview of World Congress programming, including plenaries, education tracks and more
  • Tips and Tricks for getting the most out of your partnering meetings
  • Tutorial of the BIO One-on-One Partnering system
  • Q&A with Webinar Presenters

In 2017, the BIO World Congress hosted 2,130 partnering meetings in just 3 days – a 9% increase from the number of meetings held in 2016. And with a 123% increase in partnering meetings since the 2014 World Congress, we expect 2018 to be even bigger. Don’t miss out on making lasting partnerships at the 2018 World Congress and be sure to view the Partnering Webinar.

If you haven’t done so yet, register to attend the 2018 World Congress.

And for those that have already registered to attend the World Congress in July and received their login information, BIO’s One-on-One Partnering is now open. Start building out your company’s profile and use BIO’s tips and tricks to get a head start, so you can begin partnering day one in Philadelphia!